| 摘要 |
<p>Discloses anti-BCMA antibodies comprising CDRs derived from antibodies C11D5, C12A3 and C13F12. Further disclosed are hybridomas producing the antibodies and pharmaceutical compositions comprising the antibodies. Further disclosed is the use of the antibodies to treat B-cell related conditions.</p> |
